8-K: Cavitation Technologies Agrees to $35M Acquisition

Cavitation Technologies, Inc. has entered into a definitive tender offer agreement with European Guarantee Services S.A.R.L. for an acquisition valued at $35 million.

Summary

• Cavitation Technologies, Inc. (CVAT) has signed a definitive tender offer agreement with European Guarantee Services S.A.R.L. (Purchaser) to acquire all outstanding shares of CVAT for a total of $35 million in cash, less outstanding indebtedness and liabilities.
• The Purchaser will commence a tender offer for CVAT shares within 10 business days of the agreement date, with an initial offer price per share to be determined based on the Net Price and outstanding shares as of the agreement date.
• A final offer price will be determined approximately 45 business days after the offer commencement, adjusted for final indebtedness, liabilities, and any new shares issued.
• The transaction also includes a concurrent offer by the Purchaser to acquire Alchemy Beverages Inc. (Alchemy), in which CVAT holds a 17% stake, for $7 million.
• The acquisition is subject to several conditions, including the successful acquisition of Alchemy shares and the tender of at least 90% of CVAT's outstanding shares.
• The agreement was executed on August 14, 2026, and the company expects to file a Form 8-K with the SEC within three business days.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development, indicating a significant cash infusion and potential exit for shareholders, though the final offer price is subject to adjustments.

Positives

• A definitive agreement for a $35 million cash acquisition provides a clear exit strategy for shareholders.
• The agreement includes a concurrent acquisition of Alchemy Beverages Inc., where CVAT holds a stake, potentially realizing value from that investment.
• The company's board of directors has unanimously recommended the transaction, deeming it fair and in the best interests of shareholders.
• The tender offer structure allows shareholders to review the terms and decide whether to tender their shares.
• The company maintains its reporting status and OTC listing during the process, ensuring continued transparency.

Negatives

• The final offer price per share is subject to adjustment based on the company's final indebtedness, liabilities, and outstanding shares as of a future record date.
• The acquisition is contingent on the successful completion of the separate tender offer for Alchemy Beverages Inc.
• A minimum of 90% of CVAT's outstanding shares must be tendered for the offer to be successful.
• The transaction is subject to regulatory review, including by CFIUS, which could potentially block the deal.
• The company has significant outstanding warrants and convertible rights, which could dilute the effective offer price per share if exercised.

Risks

• The final offer price is subject to adjustments based on the company's financial condition at a future date.
• The transaction is conditional on the successful acquisition of Alchemy Beverages Inc.
• A minimum tender condition of 90% of outstanding shares must be met.
• Regulatory approvals, including from CFIUS, are required and could prevent the transaction.
• The company has a substantial number of outstanding warrants and convertible rights that could be exercised, potentially impacting the final per-share price.
• The agreement can be terminated under certain conditions, including if regulatory actions permanently prohibit the transaction or if a Material Adverse Effect occurs.

Future Outlook

The company will undergo a tender offer process where a purchaser will seek to acquire all outstanding shares for $35 million in cash, subject to adjustments and conditions. The offer period will be at least 60 business days, with potential extensions to allow shareholders to review amended offer documents and the final offer price. The transaction is expected to be completed following the satisfaction or waiver of all offer conditions.

Management Comments

• "The execution of this definitive tender offer agreement with EGS represents a monumental milestone for Cavitation Technologies and our shareholders," said Neil Voloshin, Chief Executive Officer of CVAT.
• "We have worked diligently with EGS to finalize this $35 million agreement, and we look forward to the execution of the Alchemy agreement in the coming days."
• "We remain fully committed to working through the regulatory process and completing all necessary SEC filings to bring this transaction to a successful conclusion."

Industry Context

StockSavvy.ai notes that this tender offer agreement signifies a potential acquisition of a nanotechnology solutions provider by a financial and wealth management company. Such transactions often occur when a strategic buyer sees value in a company's technology or market position, or when a financial firm identifies an opportunity for a profitable exit for shareholders.

Comparison to Industry Standards

• The offer price of $35 million for Cavitation Technologies, Inc. is a significant cash transaction for a company operating in the nanotechnology sector.
• The concurrent acquisition of a 17% stake in Alchemy Beverages Inc. for $7 million suggests a bundled transaction strategy, common in M&A to achieve synergies or consolidate related assets.
• The tender offer structure, requiring at least 90% shareholder participation, is a standard approach for achieving full control in such acquisitions.
• The inclusion of conditions related to CFIUS review aligns with increasing scrutiny of foreign investments in U.S. technology companies.

Related Party Transactions

• On May 20, 2025, 5,000,000 shares were issued to Union Consulting Limited for services related to introducing the Company and the Buyer for the transaction.

Stakeholder Impact

• Shareholders will have the opportunity to tender their shares for cash consideration, providing a potential liquidity event.
• The company's employees (two in total) may be impacted by the change in ownership, though the agreement states no payments or increased benefits are triggered by the transaction.
• Creditors may be affected by the company's liabilities being factored into the final offer price.

Next Steps

• Purchaser will commence the tender offer within 10 business days of the Effective Date.
• The Offer to Purchase and related documents will be filed with the SEC on Schedule TO.
• The Company will file a Schedule 14D-9 with the SEC.
• A final offer price will be determined approximately 45 business days after the offer commencement.
• Amended offer documents will be disseminated to shareholders.
• The offer period will be extended to allow shareholders at least 30 business days to review the amended offer and final recommendation.
• Subject to satisfaction of Offer Conditions, Purchaser will accept and pay for tendered shares.

Key Dates

Recommendation

The offer provides a clear cash exit at $35 million, which is a significant premium over recent trading prices. However, the final price is subject to adjustments, and the 90% tender condition introduces uncertainty. Given these factors, a 'hold' recommendation is prudent, allowing shareholders to await the final offer price and assess the likelihood of the transaction closing, while acknowledging the potential for a positive outcome.

Keywords

tender offer, acquisition, merger, Cavitation Technologies, European Guarantee Services, Alchemy Beverages, shareholder value, cash consideration